Results 11 to 20 of about 456,204 (268)
Genome Medicine, 2021 Background Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies.
Clément Meiller +21 more
doaj +1 more source
MicroRNAs in Solid Tumors [PDF]
Journal of Surgical Research, 2009 MicroRNAs (miRNAs or miRs) are small, noncoding RNAs (approximately 20-22 nucleotides) that have critical functions in cell proliferation, apoptosis, and differentiation. These evolutionarily conserved RNA sequences are the result of a complex sequence of processing steps, which can regulate the expression of tens, and even hundreds, of genes.
Mary, Dillhoff +2 more
openaire +2 more sources
Chronotherapeutics for Solid Tumors
Pharmaceutics, 2023 Circadian rhythms are internal manifestations of the 24-h solar day that allow for synchronization of biological and behavioral processes to the external solar day. This precise regulation of physiology and behavior improves adaptive function and survival.
Claire O. Kisamore +4 more
openaire +3 more sources
Pediatrics & Neonatology, 2018 Neonatal tumors are different from tumors of the older children and knowledge gained from treating older children can not be extrapolated to neonates. Neonates have immature physiology and their haematopoietic and immune systems are not fully developed and the response to therapy is unpredictable.
openaire +3 more sources
Metastasis and Tumor Cell Migration of Solid Tumors [PDF]
Cancers, 2021 The developmental process of local and distant metastases represents the major and defining trait of malignant tumors, whereby tumor cells sustain the capability to migrate from the initial tumor site, seed, and grow at a location other than that of the initial tumor [...]
Jens Hoeppner, Peter Bronsert
openaire +3 more sources
Journal for ImmunoTherapy of Cancer, 2019 Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g ...
Gaia Griguolo +4 more
doaj +1 more source
Nature Communications, 2023 Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung ...
Irati Macaya +31 more
doaj +1 more source
Tumor–platelet interaction in solid tumors [PDF]
International Journal of Cancer, 2012 AbstractElevated platelet counts in patients diagnosed with malignant tumors were first described more than 100 years ago. Today it is well known that in many types of solid tumors, thrombocytosis at the time of diagnosis is associated with shorter survival.
Daniel, Buergy +3 more
openaire +2 more sources
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
npj Breast Cancer, 2021 Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be
Francesco Schettini +26 more
doaj +1 more source
Molecular Oncology, 2020 Development of precision medicine for malignant pleural mesothelioma (MPM) requires a deep knowledge of tumor heterogeneity. Histologic and molecular classifications and histo‐molecular gradients have been proposed to describe heterogeneity, but a deeper
Lisa Quetel +20 more
doaj +1 more source